Medicare locks in wound-care prices, FDA fast-tracks tissue products

What it does

This bill creates a new Medicare payment system for skin substitute products (cellular or tissue-based wound treatments) starting January 2026, setting initial reimbursement based on 2023 pricing data and tying future increases to inflation. It also requires Medicare to identify high-billing providers of these products for fraud review, implement prior authorization for outlier providers, and directs the FDA to streamline approval processes for human tissue products while maintaining safety standards. The bill benefits wound-care manufacturers and regenerative medicine companies by establishing stable, predictable Medicare reimbursement; patients may benefit from faster FDA approval timelines, though the fraud-monitoring provisions suggest concern about overutilization.

Why we flagged it

The bill's core function is establishing a new Medicare reimbursement pathway for skin substitute products and streamlining FDA approval for tissue-based therapies. While framed as 'access and reform,' the primary mechanism is a payment-rate lock tied to 2023 baseline data, which directly benefits manufacturers by guaranteeing stable reimbursement.

What the text implies

• The 2023 volume-weighted average payment lock may insulate manufacturers from price competition indefinitely, as future increases are capped at inflation rather than market-driven adjustments.
• The 'reasonable and necessary portion' definition (greater of 3 sq cm or 120% of wound size) effectively guarantees reimbursement for up to 20% product wastage, shifting waste costs to Medicare rather than manufacturers.
• FDA streamlining for tissue products may reduce pre-market clinical evidence requirements, potentially accelerating market entry for products with limited long-term safety data.
• The outlier-provider fraud monitoring (top 3% by payment volume) may disproportionately target high-volume wound-care centers in rural or underserved areas, potentially reducing access in those regions.
• Consolidated billing code (Section 2.7) creates a single reimbursement pathway, eliminating granular product differentiation and potentially favoring larger manufacturers with broader product portfolios.

Who it affects

Patients with chronic wounds may gain faster access to advanced treatments through FDA streamlining and stable Medicare coverage. However, the bill's payment methodology locks in 2023 pricing indefinitely (with only inflation adjustments), potentially limiting manufacturer innovation incentives and future cost competition. The fraud-monitoring provisions protect Medicare from abuse but may also create barriers to legitimate access if prior authorization becomes burdensome.

Who stands to gain

• Skin substitute product manufacturers (e.g., Organogenesis, Mimedx, Apligraf producers)
• Regenerative medicine companies
• Tissue banks and procurement organizations
• Wound-care clinics and surgical centers

Named in the bill

Medicare, Social Security Act (Section 1861, 1847A, 1833, 1834), FDA (Food and Drug Administration), HHS (Department of Health and Human Services), CMS (Centers for Medicare & Medicaid Services), OIG (Office of Inspector General), Federal Supplementary Medical Insurance Trust Fund, Organogenesis, Mimedx, Apligraf, Tissue banks, Wound-care clinics

Where it stands

2 cosponsors: 2 Republicans.

• Dec 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 18, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

10 lobbying clients named this bill on 11 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $635,979 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 91% of bills with at least one filing.

Gabe Evans, the sponsor, reported $1,523,467 in PAC receipts in the 2026 cycle.

• National Association of Accountable Care Organizations — $142,230 on 1 filing
• Convatec, Inc. F/k/a Triad Life Sciences, Inc. — $90,000 on 1 filing
• Organogenesis Inc. — $80,000 on 1 filing
• Acesso Biologics — $60,000 on 1 filing
• Biowound Solutions — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.